150,246 members

Skip to content. | Skip to navigation

South Central Respiratory Programme

NICE update on rofumilast (Daxas)

Network navigation

NICE update on rofumilast (Daxas)

NICE has updated its guidance on the use of rofumilast (Daxas) for severe COPD, saying it should only be used in the context of a clinical trial.

NICE recommends roflumilast for people with severe COPD only if they are taking part in a research study (clinical trial) that is investigating using roflumilast at the same time as a bronchodilator.

This is because NICE has found there is not enough evidence about how well it works or about the best way to use it for it to be recommended for general use within the NHS.

> Read more about the assessment on the NICE website